Form 4: Aclaris CBO Amends RSU Tax Withholding Report

Aclaris Therapeutics' Chief Business Officer, James Loerop, filed an amended Form 4 to correct the number of shares withheld for tax obligations related to restricted stock unit vesting.

Summary

• James Loerop, Chief Business Officer of Aclaris Therapeutics, Inc. (ACRS), filed an amended Form 4.
• The amendment corrects the number of shares previously reported as withheld by the issuer to satisfy tax obligations.
• The original transaction involved the withholding of 15,980 shares of Common Stock at a deemed price of $2.48 per share.
• This withholding was in connection with the vesting and settlement of restricted stock units.
• Following the reported transaction, Mr. Loerop beneficially owns 102,773 shares.
• The correction will affect the amount of securities beneficially owned in subsequent filings.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing. It reports a routine tax withholding transaction and an amendment to correct a previous report, neither of which inherently indicates positive or negative operational or financial performance.

Future Outlook

The filing indicates that the adjustment to the number of shares withheld will affect the amount of securities beneficially owned following the reported transaction in subsequent filings. No other forward-looking statements are provided.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard regulatory disclosures for insider transactions. The amendment for tax withholding related to RSU vesting is a routine administrative correction, common in companies where executive compensation includes equity awards. This type of filing typically does not reflect strategic shifts or operational performance, unlike earnings reports or major corporate announcements.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure for insider transactions. It does not contain information that allows for a direct comparison to industry-specific operational or financial benchmarks.
• The transaction itself (tax withholding for RSU vesting) is a common practice across publicly traded companies that grant equity compensation.

Related Party Transactions

• The transaction involves the withholding of shares by the issuer (Aclaris Therapeutics, Inc.) from an officer (James Loerop) to satisfy tax obligations related to his compensation. This is a standard related-party transaction within the scope of executive compensation.

Stakeholder Impact

• Minimal direct impact on shareholders, employees, customers, suppliers, or creditors, as this is a routine administrative correction related to executive compensation. It reflects standard equity compensation practices.

Next Steps

• The correction made in this amendment will be reflected in subsequent filings regarding James Loerop's beneficial ownership.

Key Dates

Keywords

Aclaris Therapeutics, ACRS, Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, RSU Vesting, Tax Withholding, Amendment, James Loerop, Chief Business Officer